Detail akcie Allarity Rg online

Business Summary: Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. It is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its therapeutic candidate, stenoparib, is a dual inhibitor of the key DNA damage repair enzyme PARP, as well as Tankyrases, critical enzymes involved in the WNT signaling pathway commonly activated in many cancers. Inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancers (ovarian cancers). The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Allarity Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders decreased 56% to $7.9M. Lower net loss reflects Impairment of intangible assets decrease from $9.7M (expense) to $0K, General and Administartive - Balancingv decrease of 24% to $4.5M (expense), Foreign exchange gains (losses) increase from $69K to $1.3M (income).